San Jose, California (PRWEB) September 25, 2013
Follow us on LinkedIn – Enzyme-Linked Immunosorbent Assay (ELISA) is one of the few assay formats to find widespread popularity in a rapidly changing life sciences and drug discovery market. However, over the last few years, the market has been witnessing negative growth due to the adoption of new technologies by researchers, particularly multiplex proteomic array platforms. The growing preference for multiplex proteomic arrays has been cannibalizing the popularity of ELISA. Growth in the market is thereby being restricted only to laboratories seeking cost-effective technology options. In addition to the competitive threat posed by multiplex assays, manufacturers have been facing a major challenge in the form of increasing commoditization of ELISA products. Commoditization of ELISA products has intensified pricing pressures for manufacturers. To counter the challenges, manufacturers are targeting niche markets and are focusing on the development of innovative products.
Although the new multiplex proteomic array technology has dented sales of ELISA products, demand will continue to hold ground in the short to medium term owing in part to its use as a secondary validation process by multiplex customers. This is largely due to the quality and established credential of Research ELISA products. Cost-effective Research ELISA products are preferred by laboratories and researchers dealing with less number of analytes and high sensitivity of assays. Another factor enabling ELISA’s sustenance in the immunoassay market is the development of automated platforms. These platforms, specifically designed for running ELISA, offer improved perfor
Copyright©2012 Vocus, Inc.
All rights reserved